Non-linear pharmacokinetics of MDMA ('ecstasy') in humans
about
MDMA and the “Ecstasy Paradigm”Toxicity of amphetamines: an updateNeural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA)Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humansCustomizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applicationsThe norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humansThe pharmacology and toxicology of "ecstasy" (MDMA) and related drugsClinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT)In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity.Ecstasy: are animal data consistent between species and can they translate to humans?Quantitative determination of paroxetine and its 4-hydroxy-3-methoxy metabolite in plasma by high-performance liquid chromatography/electrospray ion trap mass spectrometry: application to pharmacokinetic studies.Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related AnalogsCritical role of peripheral vasoconstriction in fatal brain hyperthermia induced by MDMA (Ecstasy) under conditions that mimic human drug use3,4-Methylenedioxymethamphetamine administration on postnatal day 11 in rats increases pituitary-adrenal output and reduces striatal and hippocampal serotonin without altering SERT activity.Mice lacking multidrug resistance protein 1a show altered dopaminergic responses to methylenedioxymethamphetamine (MDMA) in striatumThe role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivativesMDMA effects consistent across laboratories.A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA.A mechanistic insight into 3,4-methylenedioxymethamphetamine ("ecstasy")-mediated hepatotoxicity.The mixture of "ecstasy" and its metabolites is toxic to human SH-SY5Y differentiated cells at in vivo relevant concentrations.A comprehensive review of MDMA and GHB: two common club drugs.Baths salts, spice, and related designer drugs: the science behind the headlines.A methoxydiphenidine-impaired driver.Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research.3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings.Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug usersBJCP 40th anniversary: moving forward, looking back.The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent Resting State Functional Connectivity.Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals.The effect of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamusMetabolism and disposition of 3,4-methylenedioxymethamphetamine ("ecstasy") in baboons after oral administration: comparison with humans reveals marked differences.Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice.Preventing problems in Ecstasy users: reduce use to reduce harm.Negative experiences on Ecstasy: the role of drug, set and setting.Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans.Direct comparison of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") disposition and metabolism in squirrel monkeys and humans.MDMA and metabolite disposition in expectorated oral fluid after controlled oral MDMA administration.The spatial epidemiology of cocaine, methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) use: a demonstration using a population measure of community drug load derived from municipal wastewater.Effects of repeated 3,4-methylenedioxymethamphetamine administration on neurotransmitter efflux and sensory-evoked discharge in the ventral posterior medial thalamus.Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans.
P2860
Q21558618-7C0F7291-0E3D-432D-A3F3-971187DFAA07Q22252794-86DD233D-82EC-4D1F-A865-F01F9F67EBE8Q24619949-4A7DDCD6-94C0-4D0E-B920-B772F1B70FE3Q26859367-C1901650-A257-4C61-A27A-37FC97B51BD1Q26864041-25629450-53A9-4EC2-A4CE-E68F3349D342Q28240897-03C4C573-1ACA-48E9-9224-3C8C9935485DQ28361466-E867AA80-741C-4999-9D14-17296456052FQ28484562-5DFE17DD-611C-4B13-9A9E-F28B66D03217Q30535782-EC3BAC3A-7E89-4873-977D-EF7B87891E64Q31033315-F4BE9369-05AF-429A-9DCC-8CBBBB16EB1BQ33427045-01B00F62-2C01-483D-A57A-1FFEB4D69544Q33566201-E9D348F8-FC38-4D94-8148-227759729051Q33707843-C861FDAA-DE4A-443C-AC35-9C77B8F077D0Q33923908-9F831223-1460-4345-BAD9-878A4296CC0AQ34051713-160E18D3-C01E-41E3-9D34-39CCF64AAA43Q34112933-F6D419C8-EECA-49C8-AC98-35277533EEFBQ34167689-1F22622D-DAFD-4D48-BDBC-A3C21C715547Q34190116-819733FB-E847-48DA-B513-99DF67797BC1Q34239110-79EC6B2D-25A0-4B54-95AB-7E4B7E1BEBB5Q34375859-E1D72903-341F-4FF4-AD8D-50B7CBEC5C47Q34476901-DCD393DB-D149-4B33-8416-194A15B1E29FQ34491601-6819AE6B-3BC4-4B47-9CCC-4984FC42451DQ34498613-BE786FFF-94F6-4D22-8404-4FB45DA7B6A9Q34528465-98E13DA0-F3F1-408F-B67C-765C54354C4EQ34565712-054DDB27-15EA-419E-974E-530041194088Q34634128-127A3B67-C870-42A3-8012-555D2F029B2FQ34635476-2E513D1E-0131-4DF4-8BC7-464EFCCA2EF4Q34659485-D65FE5C6-29B1-44C7-81EA-FBD26B3F2F80Q35000765-E6439575-32B8-4A3C-A5CE-84166A9DA8BCQ35044080-D56BDE8A-9A98-4804-A165-CCCB6A4DD404Q35077922-95E55BFC-B566-48CC-AD25-F1CF634352E6Q35079542-C4F20B12-DFC1-40ED-BA25-1B0A58F44BA1Q35105557-33F636AC-EAE0-4D38-9E3F-A096D2414F9BQ35105569-965370E4-1896-476E-A640-6C26567EC8A9Q35175998-F0A88B23-8213-4780-85C9-5C9E9846CF57Q35176011-0A903D47-640E-428C-B2F0-CAB0BEBE98BFQ35228063-58241F02-A79F-425E-AC0B-A2A2E593C816Q35576210-FC4EEAC2-4F62-4BAF-BF72-39CC5F85F465Q35650765-2C3F5C8E-FBB3-4ED8-8964-ACB25E12C54CQ35953819-BB776D0B-C06F-4D7E-B2A6-2E85CCF88C40
P2860
Non-linear pharmacokinetics of MDMA ('ecstasy') in humans
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
Non-linear pharmacokinetics of MDMA ('ecstasy') in humans
@ast
Non-linear pharmacokinetics of MDMA ('ecstasy') in humans
@en
Non-linear pharmacokinetics of MDMA
@nl
type
label
Non-linear pharmacokinetics of MDMA ('ecstasy') in humans
@ast
Non-linear pharmacokinetics of MDMA ('ecstasy') in humans
@en
Non-linear pharmacokinetics of MDMA
@nl
prefLabel
Non-linear pharmacokinetics of MDMA ('ecstasy') in humans
@ast
Non-linear pharmacokinetics of MDMA ('ecstasy') in humans
@en
Non-linear pharmacokinetics of MDMA
@nl
P2093
P2860
P1476
Non-linear pharmacokinetics of MDMA ('ecstasy') in humans
@en
P2093
R Brenneisen
P2860
P304
P356
10.1046/J.1365-2125.2000.00121.X
P407
P577
2000-02-01T00:00:00Z